Loading...
Rituxan, Truxima, Ruxience
Biologic • Anti-CD20 monoclonal antibody
Half-life
22 days (after first dose); 76 days (after fourth dose)
Protein Binding
N/A
Metabolized By
Proteolytic degradation
External
Drugs.comChimeric antibody targeting CD20 on B lymphocytes, causing B-cell depletion
Drug Class
Biologic
Subclass
Anti-CD20 monoclonal antibody
Half-life
22 days (after first dose); 76 days (after fourth dose)
Time for plasma concentration to decrease by 50%
Protein Binding
N/A
Fraction bound to plasma proteins
Therapeutic Index
Wide
Margin between therapeutic and toxic doses